WO2001021194A3 - Method for the therapeutic management of endometriosis and fallopian tube obstruction - Google Patents

Method for the therapeutic management of endometriosis and fallopian tube obstruction Download PDF

Info

Publication number
WO2001021194A3
WO2001021194A3 PCT/EP2000/009212 EP0009212W WO0121194A3 WO 2001021194 A3 WO2001021194 A3 WO 2001021194A3 EP 0009212 W EP0009212 W EP 0009212W WO 0121194 A3 WO0121194 A3 WO 0121194A3
Authority
WO
WIPO (PCT)
Prior art keywords
contraceptive
fallopian tube
present
therapeutic management
endometriosis
Prior art date
Application number
PCT/EP2000/009212
Other languages
French (fr)
Other versions
WO2001021194A2 (en
Inventor
Juergen Engel
Hilde Riethmueller-Winzen
Ricardo Felberbaum
Klaus Diedrich
Wolfgang KUEPKER
Original Assignee
Zentaris Ag
Juergen Engel
Riethmueller Winzen Hilde
Ricardo Felberbaum
Klaus Diedrich
Wolfgang KUEPKER
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP00967722A priority Critical patent/EP1214086A2/en
Priority to MXPA02002436A priority patent/MXPA02002436A/en
Application filed by Zentaris Ag, Juergen Engel, Riethmueller Winzen Hilde, Ricardo Felberbaum, Klaus Diedrich, Wolfgang KUEPKER filed Critical Zentaris Ag
Priority to CA002383510A priority patent/CA2383510A1/en
Priority to UA2002043346A priority patent/UA73956C2/en
Priority to JP2001524618A priority patent/JP2003509467A/en
Priority to BR0014198-4A priority patent/BR0014198A/en
Priority to PL353244A priority patent/PL201898B1/en
Priority to IL14818500A priority patent/IL148185A0/en
Priority to SK375-2002A priority patent/SK3752002A3/en
Priority to HU0202741A priority patent/HUP0202741A3/en
Priority to AU77792/00A priority patent/AU769482B2/en
Publication of WO2001021194A2 publication Critical patent/WO2001021194A2/en
Publication of WO2001021194A3 publication Critical patent/WO2001021194A3/en
Priority to NO20021430A priority patent/NO331198B1/en
Priority to BG106584A priority patent/BG66128B1/en
Priority to HK03101215.4A priority patent/HK1049117A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides a method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction by short term induction treatment with an LH-RH antagonist for 4 to 12 weeks. According to another aspect of the present invention, the short term LH-RH treatment is followed by the combined or separate administration of one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof. According to a further aspect of the present invention a pharmaceutical composition comprising an LHRH antagonist and one or more active agents selected from the group consisting of a contraceptive, preferably an oral contraceptive, a non-steroidal anti-rheumatic agent, an analgetic, an androgen other than a 17-alpha-alkyl substituted testosterone or any combinations thereof are provided.
PCT/EP2000/009212 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction WO2001021194A2 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SK375-2002A SK3752002A3 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
IL14818500A IL148185A0 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
CA002383510A CA2383510A1 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometreial tissue, chronic pelvic pain and fallopian tube obstruction
MXPA02002436A MXPA02002436A (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction.
JP2001524618A JP2003509467A (en) 1999-09-23 2000-09-20 Method for treating extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
BR0014198-4A BR0014198A (en) 1999-09-23 2000-09-20 Process for the therapeutic management of extra-uterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
HU0202741A HUP0202741A3 (en) 1999-09-23 2000-09-20 Pharmaceutical composition available for the therapeutic management of endometriosis and fallopian tube obstruction and process for its preparation
EP00967722A EP1214086A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction
UA2002043346A UA73956C2 (en) 1999-09-23 2000-09-20 Method for therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction due to extrauterine proliferation of endometrial tissue
PL353244A PL201898B1 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
AU77792/00A AU769482B2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction
NO20021430A NO331198B1 (en) 1999-09-23 2002-03-21 Use of the LHRH antagonist for the manufacture of a drug for therapeutically controlling extrauterine endometrial proliferation, chronic pelvic pain and fallopian tube obstruction
BG106584A BG66128B1 (en) 1999-09-23 2002-04-05 Pharmaceutical composition and use for the therapeutic management of extrauterine proliferation of endometrial tissue
HK03101215.4A HK1049117A1 (en) 1999-09-23 2003-02-18 Method for the therapeutic management of extrauterine proliferation of endometrial tissue, chronic pelvic pain and fallopian tube obstruction

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15547899P 1999-09-23 1999-09-23
US60/155,478 1999-09-23

Publications (2)

Publication Number Publication Date
WO2001021194A2 WO2001021194A2 (en) 2001-03-29
WO2001021194A3 true WO2001021194A3 (en) 2002-03-14

Family

ID=22555601

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/009212 WO2001021194A2 (en) 1999-09-23 2000-09-20 Method for the therapeutic management of endometriosis and fallopian tube obstruction

Country Status (22)

Country Link
EP (1) EP1214086A2 (en)
JP (2) JP2003509467A (en)
KR (1) KR100772852B1 (en)
CN (2) CN101045155A (en)
AU (1) AU769482B2 (en)
BG (1) BG66128B1 (en)
BR (1) BR0014198A (en)
CA (1) CA2383510A1 (en)
HK (1) HK1049117A1 (en)
HU (1) HUP0202741A3 (en)
IL (1) IL148185A0 (en)
MX (1) MXPA02002436A (en)
NO (1) NO331198B1 (en)
NZ (1) NZ534836A (en)
PL (1) PL201898B1 (en)
RU (1) RU2255759C2 (en)
SK (1) SK3752002A3 (en)
TR (1) TR200200738T2 (en)
TW (1) TWI267373B (en)
UA (1) UA73956C2 (en)
WO (1) WO2001021194A2 (en)
ZA (1) ZA200201374B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10157628A1 (en) * 2001-11-26 2003-06-12 Zentaris Ag Solution for injection of an LHRH antagonist
US7214662B2 (en) 2001-11-27 2007-05-08 Zentaris Gmbh Injectable solution of an LHRH antagonist
BRPI0906404B8 (en) 2008-01-24 2021-05-25 Univ Louisiana State construction of lytic domain fusion, its uses, pharmaceutical composition, as well as a process to selectively reduce or inhibit the proliferation of a cell expressing a receptor, ligand or antigen
US20120053122A1 (en) * 2009-01-22 2012-03-01 Maatschap Interne Geneeskunde Rijnstate Method for the prophylaxis or treatment of flushing
EP4035685A1 (en) 2012-10-30 2022-08-03 Esperance Pharmaceuticals, Inc. Antibody/drug conjugates and methods of use
EP2968566A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding and uterine fibroids
WO2019203870A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
EP3560555A1 (en) * 2018-04-26 2019-10-30 LifeArc A composition for treating one or more estrogen related diseases

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997027863A1 (en) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
WO2000055190A1 (en) * 1999-03-17 2000-09-21 Zentaris Ag Novel lhrh antagonists with improved solubility characteristics

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064939A (en) * 1990-02-06 1991-11-12 The Salk Institute For Biological Studies Cyclic gnrh antagonists
SE9301606D0 (en) * 1993-05-07 1993-05-07 Per-Christer Oden COMPOSITION FOR THE TREATMENT OF IMPAIRED HAIR GROWTH
AP775A (en) * 1994-07-22 1999-10-28 The Eastern Virginia Medical School Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens.
DE19513662A1 (en) * 1995-04-08 1996-10-10 Schering Ag Combined pharmaceutical preparation for hormonal contraception

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658884A (en) * 1994-07-22 1997-08-19 The Medical College Of Hampton Roads Establishment of tonic ovarian estrogen secretion for extended therapeutic regimens
WO1997027863A1 (en) * 1996-01-29 1997-08-07 Schering Aktiengesellschaft Combined pharmaceutical preparation containing lhrh-analogous substances and anti-estrogens for treating gynaecological disorders
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
WO1998055470A1 (en) * 1997-06-05 1998-12-10 Merck & Co., Inc. Antagonists of gonadotropin releasing hormone
WO2000055190A1 (en) * 1999-03-17 2000-09-21 Zentaris Ag Novel lhrh antagonists with improved solubility characteristics
DE19911771A1 (en) * 1999-03-17 2000-09-28 Asta Medica Ag New LHRH antagonists with improved solubility properties

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NORMAN P: "Cetrorelix, ASTA Medica AG", CURRENT OPINION IN ONCOLOGIC, ENDOCRINE & METABOLIC INVESTIGATIONAL DRUGS, vol. 2, no. 2, pages 227 - 248, XP000982761 *

Also Published As

Publication number Publication date
ZA200201374B (en) 2002-10-30
NZ534836A (en) 2007-07-27
RU2255759C2 (en) 2005-07-10
HUP0202741A2 (en) 2003-01-28
MXPA02002436A (en) 2003-02-12
AU769482B2 (en) 2004-01-29
PL353244A1 (en) 2003-11-03
UA73956C2 (en) 2005-10-17
PL201898B1 (en) 2009-05-29
NO20021430L (en) 2002-05-07
KR20020035879A (en) 2002-05-15
HUP0202741A3 (en) 2003-12-29
IL148185A0 (en) 2002-09-12
JP2003509467A (en) 2003-03-11
NO331198B1 (en) 2011-10-31
CA2383510A1 (en) 2001-03-29
WO2001021194A2 (en) 2001-03-29
HK1049117A1 (en) 2003-05-02
JP2012051920A (en) 2012-03-15
TR200200738T2 (en) 2002-08-21
TWI267373B (en) 2006-12-01
BG66128B1 (en) 2011-06-30
EP1214086A2 (en) 2002-06-19
BR0014198A (en) 2002-05-21
SK3752002A3 (en) 2003-06-03
BG106584A (en) 2003-02-28
CN1376070A (en) 2002-10-23
AU7779200A (en) 2001-04-24
NO20021430D0 (en) 2002-03-21
CN101045155A (en) 2007-10-03
KR100772852B1 (en) 2007-11-02

Similar Documents

Publication Publication Date Title
EP1150629A4 (en) Drug dosage unit for buccal administration of steroidal active agents
EP1337249A4 (en) Compositions and methods for administration of pharmacologically active compounds
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
FR2808685B1 (en) PHARMACEUTICAL COMPOSITIONS FOR TRANSDERMAL DELIVERY OF ANTI-INFLAMMATORY AGENTS
CA2426703A1 (en) Therapeutic agents and methods of use thereof for the modulation of angiogenesis
ITMI961152A0 (en) THERAPEUTIC COMPOSITION FOR THE TRANSDERMAL ADMINISTRATION OF AN ACTIVE INGREDIENT, ESTROGEN OR PROGESTIN OR MIXTURES THEREOF
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
NZ514574A (en) Novel method of treatment
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
HK1054918A1 (en) Compounds and compositions for delivering active agents
MXPA01008611A (en) Compounds and compositions for delivering active agents.
EE9800173A (en) Gonadotropin-releasing hormone antagonists
NZ325060A (en) Non peptide indole derivative and their use as antagonists of gonadotropin releasing hormone
MXPA03000548A (en) New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation.
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
UA37259C2 (en) Active substance for pharmaceutical compositions intended for treatment of dysfunctional metrorrhagia
HUP0400548A3 (en) Use of combinations of iop-reducing active inoredient for preparation of pharmaceutical compositions available for treatment glaucoma
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
WO2001068125A3 (en) Methods and compositions for the treatment and prevention of erectile dysfunction
WO2002015959A3 (en) Compounds and compositions for delivering active agents
PT1608349E (en) Oral delivery system comprising an antibacterial and an anti-inflammatory agent
WO2001021194A3 (en) Method for the therapeutic management of endometriosis and fallopian tube obstruction
EP1064966A3 (en) Combination of an 5HT1 receptor antagonist, caffeine and a cyclooxygenase-2 inhibitor for the treatment of migraine
MXPA01008993A (en) Combination treatment for depression and anxiety.
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 148185

Country of ref document: IL

Ref document number: IN/PCT/2002/231/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2002/01374

Country of ref document: ZA

Ref document number: 200201374

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2000967722

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 517373

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 77792/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/002436

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2383510

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PV2002-908

Country of ref document: CZ

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BG BR BY CA CN CZ DZ EE GE HR HU ID IL IN IS JP KG KR KZ LT LV MK MX NO NZ PL RO RU SG SI SK TR UA US UZ YU ZA

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 3752002

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 008131961

Country of ref document: CN

Ref document number: 1020027003740

Country of ref document: KR

Ref document number: 2002/00738

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2001 524618

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2000 106584

Country of ref document: BG

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2002 2002111000

Country of ref document: RU

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 1020027003740

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2000967722

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2002-908

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 77792/00

Country of ref document: AU